Skip Navigation
 

Funding


RCDC

Project Listing by Category


Back to Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC) Click the column headings to sort project listings.
  Help
12
CategoryFYFunding ICProject NumberSub Project #Project TitlePI NameOrg NameState / CountryAmount
Ovarian Cancer 2017 NCI 5R01CA178535-05 The contribution of rare alleles to ovarian cancer in the population GAYTHER, SIMON CEDARS-SINAI MEDICAL CENTER CA $549,009
Ovarian Cancer 2017 NCI 5U01CA194393-03 Quantifying and Characterizing the shared genetic contribution to common cancers LINDSTROEM, SARA UNIVERSITY OF WASHINGTON WA $566,464
Ovarian Cancer 2017 NIGMS 2P20GM103625-06 5373 Dysbiosis-induced impairment of tumoral leukocyte extravasation DINGS, RUUD UNIV OF ARKANSAS FOR MED SCIS AR $283,100
Ovarian Cancer 2017 NCI 1K22CA207602-01 The role of short-form Ron (sfRon) kinase in the pathogenesis of high-grade serous ovarian cancer BIENIASZ, MAGDALENA OKLAHOMA MEDICAL RESEARCH FOUNDATION OK $159,705
Ovarian Cancer 2017 OD 1R56CA198492-01A1 Integrated Nano-Therapeutics to Overcome Tumor Plasticity and Resistance AMIJI, MANSOOR NORTHEASTERN UNIVERSITY MA $299,852
Ovarian Cancer 2017 NIAID 5R01AI109008-05 Origin of the innate immunity suppression caused by nairovirus' protease activity PEGAN, SCOTT UNIVERSITY OF GEORGIA GA $308,767
Ovarian Cancer 2017 NIAID 5R01AI033993-23 Processed Antigen Characterization by Mass Spectrometry HUNT, DONALD UNIVERSITY OF VIRGINIA VA $615,162
Ovarian Cancer 2017 NCI 5R01CA043054-30 Nuclear Function of Abl in DNA Damage Response WANG, JEAN UNIVERSITY OF CALIFORNIA SAN DIEGO CA $387,500
Ovarian Cancer 2017 NIBIB 5R01EB019458-03 Pre-clinical quantitation of ovarian cancer tumor burden using Magnetic Particle Imaging and non-dilutive cell labeling CONOLLY, STEVEN UNIVERSITY OF CALIFORNIA BERKELEY CA $477,914
Ovarian Cancer 2017 NCI 5R01CA194498-02 CDK12 in Ovarian Cancer KARNITZ, LARRY MAYO CLINIC ROCHESTER MN $393,220
Ovarian Cancer 2017 NCI 5R01CA202919-02 Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer ZHANG, RUGANG WISTAR INSTITUTE PA $434,625
Ovarian Cancer 2017 NCI 5R01CA193511-02 NOX4 mediates oxidative stress in ovarian tumor growth and treatment response JIANG, BINGHUA THOMAS JEFFERSON UNIVERSITY PA $356,850
Ovarian Cancer 2017 NCI 5R01CA194064-03 Combination Therapy of OvCA with Oligonucleotides and Photodynamic Therapy MING, XIN WAKE FOREST UNIVERSITY HEALTH SCIENCES NC $283,650
Ovarian Cancer 2017 NCI 5R03CA191527-02 Deletion of Arid1a and Kras as a Model of Endometriosis-Associated Ovarian Cancer HAWKINS, SHANNON INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS IN $84,148
Ovarian Cancer 2017 NCI 5R01CA202846-02 Targeted therapy of peritoneal carcinomatosis using theranostic nanoparticles YANG, LILY EMORY UNIVERSITY GA $411,268
Ovarian Cancer 2017 NCI 5R21CA194965-02 Evolving Model of Cancer Susceptibility Testing: Clinical Decisions & Outcomes SCHWARTZ, MARC GEORGETOWN UNIVERSITY DC $169,106
Ovarian Cancer 2017 NCI 5R01CA136494-09 Molecular Mechanism of Antiangiogenic Properties of Gold Nanoparticle MUKHERJEE, PRIYABRATA UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR OK $304,695
Ovarian Cancer 2017 NCI 5R01CA190498-03 gp130 as a novel therapeutic target in ovarian cancer NEAMATI, NOURI UNIVERSITY OF MICHIGAN MI $376,320
Ovarian Cancer 2017 NCI 5R01CA136512-07 BRCA1 Function in Post-Damage Nuclear Foci LIVINGSTON, DAVID DANA-FARBER CANCER INST MA $515,452
Ovarian Cancer 2017 NCI 5R01CA174470-26 Stimulation of Tumorigenesis by NKG2D SPIES, THOMAS FRED HUTCHINSON CANCER RESEARCH CENTER WA $568,459
Ovarian Cancer 2017 NCI 5R01CA172743-05 Impact of BRCA Testing on Newly Diagnosed U.S. Breast Cancer Patients SUTPHEN, REBECCA UNIVERSITY OF SOUTH FLORIDA FL $678,656
Ovarian Cancer 2017 NCI 5R01CA186700-03 Study of biomarkers in ovarian cancer: modulation by activity & diet intervention THOMSON, CYNTHIA UNIVERSITY OF ARIZONA AZ $630,790
Ovarian Cancer 2017 NCI 5R01CA119171-10 Nutrition and Physical Activity Assessment Study (NPAAS) NEUHOUSER, MARIAN FRED HUTCHINSON CANCER RESEARCH CENTER WA $799,090
Ovarian Cancer 2017 NCI 5R01CA047135-27 Merging Marine-Derived Cytotoxic Natural Products With Experimental Therapeutics CREWS, PHIL UNIVERSITY OF CALIFORNIA SANTA CRUZ CA $636,410
Ovarian Cancer 2017 NCI 5R01CA203348-02 Blocking NK cell shedding of CD16a to increase cancer cell killing WALCHECK, BRUCE UNIVERSITY OF MINNESOTA MN $444,991
Ovarian Cancer 2017 NCI 5R01CA109298-13 Ovarian Cancer: Mechanisms of Neuroendocrine Regulation SOOD, ANIL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $356,980
Ovarian Cancer 2017 NCI 5R01CA196631-02 A network platform to connect drug response and prognosis phenotypes for cancers LI, HU MAYO CLINIC ROCHESTER MN $395,911
Ovarian Cancer 2017 NCI 5R01CA184088-03 Liposomal Doxorubicin and Pluronic Combination for Cancer Therapy KABANOV, ALEXANDER UNIV OF NORTH CAROLINA CHAPEL HILL NC $344,549
Ovarian Cancer 2017 NCI 5R00CA179137-04 Understanding the origin,initiation,and progression of high-grade serous ovarian cancer KIM, JAEYEON INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS IN $245,221
Ovarian Cancer 2017 NCI 5UM1CA173642-05 Women's Health Initiative Cancer Survivor Cohort ANDERSON, GARNET FRED HUTCHINSON CANCER RESEARCH CENTER WA $2,260,718
Ovarian Cancer 2017 NCI 1R01CA211016-01 Immune Impact on Cancer Chemoresistance ZOU, WEIPING UNIVERSITY OF MICHIGAN MI $609,903
Ovarian Cancer 2017 NIGMS 5R01GM113940-04 NIR-activatable Prodrugs for Treating Peritoneally Metastasized Ovarian Cancers YOU, YOUNGJAE UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR OK $303,400
Ovarian Cancer 2017 NCI 5R01CA135650-08 Predictive Cancer Diagnostics and Therapy Response MOORE, ANNA MASSACHUSETTS GENERAL HOSPITAL MA $552,368
Ovarian Cancer 2017 NCI 2P30CA044579-26 5844 Women's Oncology Program - WON SHUPNIK, MARGARET UNIVERSITY OF VIRGINIA VA $52,177
Ovarian Cancer 2017 NCI 5R35CA197605-02 Mucins and immune cell interactions in ovarian cancer pathogenesis & progression CRAMER, DANIEL BRIGHAM AND WOMEN'S HOSPITAL MA $1,031,346
Ovarian Cancer 2017 NCI 1R01CA211175-01 Averting recurrent and resistant ovarian tumors WANG, QIEN OHIO STATE UNIVERSITY OH $454,502
Ovarian Cancer 2017 NCI 5R21CA181994-02 Targeted Molecular Imaging of Cell Death in Ovarian Cancer MILLWARD, STEVEN UNIVERSITY OF TX MD ANDERSON CAN CTR TX $208,800
Ovarian Cancer 2017 NCI 5R01CA190423-03 Mechanisms of PARP Inhibitor Resistance in Ovarian Cancer KAUFMANN, SCOTT MAYO CLINIC ROCHESTER MN $382,326
Ovarian Cancer 2017 NCI 1R01CA211625-01 Comparative Effectiveness of Interventions to Increase Guideline-based Genetic Counseling in Ethnically and Geographically Diverse Cancer Survivors KINNEY, ANITA UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR NM $629,227
Ovarian Cancer 2017 NCI 1R01CA211707-01 Functional Effects of Ovarian Cancer Risk Variants GAYTHER, SIMON CEDARS-SINAI MEDICAL CENTER CA $686,463
Ovarian Cancer 2017 NCI 1R01CA211932-01 Molecularly-Targeted Ultrasound in Ovarian Cancer LUTZ, AMELIE STANFORD UNIVERSITY CA $484,088
Ovarian Cancer 2017 NCI 5R01CA190176-03 Effector T Cell Trafficking in Ovarian Cancer ZOU, WEIPING UNIVERSITY OF MICHIGAN MI $513,972
Ovarian Cancer 2017 NCI 5R03CA194643-02 Communicate and LEarn About youR Variant of Uncertain Significance (CLEAR VUS) SCHERR, COURTNEY NORTHWESTERN UNIVERSITY IL $83,085
Ovarian Cancer 2017 NCI 5R01CA193249-02 Behavioral Influences on Ovarian Cancer Progression: Role of Chemoresistance LUTGENDORF, SUSAN UNIVERSITY OF IOWA IA $621,318
Ovarian Cancer 2017 NHLBI 1R34HL135226-01 Thromboprophylaxis with rosuvastatin following surgery for ovarian cancer ZWICKER, JEFFREY BETH ISRAEL DEACONESS MEDICAL CENTER MA $165,109
Ovarian Cancer 2017 NCI 1R03CA212127-01 The role of X chromosome inactivation in ovarian cancer WINHAM, STACEY MAYO CLINIC ROCHESTER MN $79,500
Ovarian Cancer 2017 NCI 5R01CA169200-05 The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer BIRRER, MICHAEL MASSACHUSETTS GENERAL HOSPITAL MA $372,320
Ovarian Cancer 2017 NCI 5R01CA172667-05 Annotating the Role of Dysregulated Inositol Phosphate Metabolism in Malignant Ca NOMURA, DANIEL UNIVERSITY OF CALIFORNIA BERKELEY CA $334,984
Ovarian Cancer 2017 NCCIH 5R01AT008824-02 Botanical derived progestins and their impact on women's health BURDETTE, JOANNA UNIVERSITY OF ILLINOIS AT CHICAGO IL $359,775
Ovarian Cancer 2017 NCI 5R01CA174904-05 Roles of Chromatin Modification in BRCA1 Dependent DNA Repair GREENBERG, ROGER UNIVERSITY OF PENNSYLVANIA PA $332,000
Ovarian Cancer 2017 NCI 5R00CA175292-04 Targeting Determinants of OvCa Metastases in Engineered 3D Microfluidic Platforms RIZVI, IMRAN MASSACHUSETTS GENERAL HOSPITAL MA $249,000
Ovarian Cancer 2017 NCI 5R01CA200231-03 PHARMACOLOGICAL MODULATION OF POLY(ADP-RIBOSE) METABOLISM TAINER, JOHN UNIVERSITY OF TX MD ANDERSON CAN CTR TX $345,984
Ovarian Cancer 2017 NCI 5R01CA142698-08 Molecular mechanism and relevance of microRNAs in DSB repair pathway choice CHOWDHURY, DIPANJAN DANA-FARBER CANCER INST MA $409,002
Ovarian Cancer 2017 NCI 5K99CA197487-02 Role of DEAD-box helicase in microRNA biogenesis and Cancer HAN, CECIL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $101,631
Ovarian Cancer 2017 NCI 1R01CA203810-01A1 Using microfluidic single cell culture to characterize cancer cell asymmetric division BUCKANOVICH, RONALD UNIVERSITY OF MICHIGAN MI $433,051
Ovarian Cancer 2017 NCI 5R01CA138835-08 The RAP80-BRCC36 Deubiquitinating Complex in DNA Repair GREENBERG, ROGER UNIVERSITY OF PENNSYLVANIA PA $317,509
Ovarian Cancer 2017 NCI 5R01CA204119-02 Early Detection of Ovarian Cancer Through Epigenetic Factors in the WHI GENKINGER, JEANINE COLUMBIA UNIVERSITY HEALTH SCIENCES NY $572,330
Ovarian Cancer 2017 NCI 5F31CA203039-02 Design and synthesis of stabilized pironetin analogs for the treatment of resistant ovarian cancers COULUP, SARA UNIVERSITY OF MINNESOTA MN $29,795
Ovarian Cancer 2017 NCI 5U10CA180860-04 Integrated Translational Genoproteomics Center at Washington University MUTCH, DAVID WASHINGTON UNIVERSITY MO $540,405
Ovarian Cancer 2017 NCI 5R01CA095175-13 Analysis of BRCA1 Recombination Functions SCULLY, RALPH BETH ISRAEL DEACONESS MEDICAL CENTER MA $328,700
Ovarian Cancer 2017 NCI 5R01CA183040-04 Ovarian cancer gene therapy using HPV pseudovirion WU, TZYY-CHOOU JOHNS HOPKINS UNIVERSITY MD $336,150
Ovarian Cancer 2017 NCI 5R21CA198263-02 Cbx-3/HP-1gamma deficiency confers anti-tumor immunity THAI, TO-HA BETH ISRAEL DEACONESS MEDICAL CENTER MA $225,765
Ovarian Cancer 2017 NCI 5R21CA205819-02 Modeling the impact of mutations in ubiquitin ligase genes on transcriptional programs in endometrial cancer LESLIE, CHRISTINA SLOAN-KETTERING INST CAN RESEARCH NY $186,398
Ovarian Cancer 2017 NCI 5R01CA169604-05 Metabolic changes in ovarian cancer cells initiated by metastasis to adipose tiss LENGYEL, ERNST UNIVERSITY OF CHICAGO IL $327,850
Ovarian Cancer 2017 NCI 5U01CA200469-02 Development of in vitro diagnostic multivariate index assay using liquid-based cervical cytology specimen and/or serum/plasma biomarkers for the detection of early stage or low-volume ovarian cancer ZHANG, ZHEN JOHNS HOPKINS UNIVERSITY MD $441,524
Ovarian Cancer 2017 NCI 5R01CA175318-03 A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian Cancer HATEFI, ARASH RUTGERS, THE STATE UNIV OF N.J. NJ $354,563
Ovarian Cancer 2017 NCI 5R01CA203971-02 Deubiquitinases in regulation of BRCA1 pathway YUAN, JIAN MAYO CLINIC ROCHESTER MN $363,713
Ovarian Cancer 2017 NCI 5R01CA182832-04 An Epigenetic Strategy for Restoring Carboplatin Sensitivity in Ovarian Cancer MATEI, DANIELA NORTHWESTERN UNIVERSITY AT CHICAGO IL $323,044
Ovarian Cancer 2017 NCI 5R01CA181543-04 Analysis of Intratumoral Crosstalk in Clonal Populations of OvarianTumor Cells BRUGGE, JOAN HARVARD MEDICAL SCHOOL MA $395,654
Ovarian Cancer 2017 NCI 5R01CA197780-02 Examining the role of the miR-181a:Wnt/B-catenin axis in ovarian cancer DIFEO, ANALISA CASE WESTERN RESERVE UNIVERSITY OH $363,581
Ovarian Cancer 2017 NCI 5R21CA191243-02 Label-free microfluidic enrichment of cancer cells from noncancer cells in ascites fluid SULCHEK, TODD GEORGIA INSTITUTE OF TECHNOLOGY GA $187,018
Ovarian Cancer 2017 NLM 5K01LM012100-03 Informatic Methods for Differential Signaling and Immune Co-Regulatory Expression ENG, KEVIN ROSWELL PARK CANCER INSTITUTE CORP NY $166,765
Ovarian Cancer 2017 NCI 5R03CA191543-02 Enhancing at-Risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer HURTADO DE MENDOZA CASAUS, ALEJANDRA GEORGETOWN UNIVERSITY DC $79,150
Ovarian Cancer 2017 NCI 1R43CA213632-01 "Modulation of Immune Checkpoints by Self-Deliverable RNAi for Adoptive Cell Transfer" WOLFSON, ALEXEY ADVANCED RNA TECHNOLOGIES, LLC CO $231,500
Ovarian Cancer 2017 NCI 1F30CA213737-01 A Systems Biology Approach to Mechanisms of PARP Inhibitor Resistance in Ovarian Cancer MCGEHEE, CORDELIA MAYO CLINIC ROCHESTER MN $44,244
Ovarian Cancer 2017 NCI 5R01CA184502-04 (PQD5) Avatar-directed Treatment for Ovarian Cancer WEROHA, SARAVUT MAYO CLINIC ROCHESTER MN $714,297
Ovarian Cancer 2017 NCI 5R01CA182413-03 Origins of Ovarian Carcinoma NIKITIN, ALEXANDER CORNELL UNIVERSITY NY $358,780
Ovarian Cancer 2017 NIBIB 1F32EB023101-01A1 Sequence- and Stereocontrolled Triazolium-containing Precise Polymers for siRNA Complexation and Delivery GOLDER, MATTHEW MASSACHUSETTS INSTITUTE OF TECHNOLOGY MA $56,694
Ovarian Cancer 2017 NCI 5R01CA115483-13 Therapeutic Targeting Agents for Ovarian Cancer LAM, KIT UNIVERSITY OF CALIFORNIA AT DAVIS CA $345,660
Ovarian Cancer 2017 NCI 1U01CA213759-01 Targeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modeling LOPEZ-BERESTEIN, GABRIEL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $515,198
Ovarian Cancer 2017 NCI 5R01CA197784-02 Comparison of 3 Modes of Genetic Counseling in High-Risk Public Hospital Patients PASICK, RENA UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CA $751,892
Ovarian Cancer 2017 NCI 5R01CA196619-02 Credentialing Ovarian Cancer Models in the Context of the Dualistic Pathway Paradigm CHO, KATHLEEN UNIVERSITY OF MICHIGAN MI $489,123
Ovarian Cancer 2017 NIMHD 5R01MD009697-02 Spatiotemporal Analysis of Disparities in Ovarian Cancer Treatment and Survival BRISTOW, ROBERT UNIVERSITY OF CALIFORNIA-IRVINE CA $386,250
Ovarian Cancer 2017 NCI 5R01CA184968-04 (PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers SIKIC, BRANIMIR STANFORD UNIVERSITY CA $509,161
Ovarian Cancer 2017 NCI 5U01CA152990-07 Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker Discovery SKATES, STEVEN MASSACHUSETTS GENERAL HOSPITAL MA $1,356,082
Ovarian Cancer 2017 NCI 5R01CA206561-02 Quantitative assessment of the role of collagen alterations in ovarian cancer CAMPAGNOLA, PAUL UNIVERSITY OF WISCONSIN-MADISON WI $418,598
Ovarian Cancer 2017 NIGMS 5SC1CA199810-03 Novel Nanotechnology Platform for Breast Cancer Treatment AKALA, EMMANUEL HOWARD UNIVERSITY DC $27,280
Ovarian Cancer 2017 NCI 5R01CA180769-09 Signaling Connections Controlling Cell Motility and Invasion SCHLAEPFER, DAVID UNIVERSITY OF CALIFORNIA SAN DIEGO CA $376,500
Ovarian Cancer 2017 NCI 5R21CA205322-02 Multiplexed exosome analyses with DNA barcoding LEE, HAKHO MASSACHUSETTS GENERAL HOSPITAL MA $199,856
Ovarian Cancer 2017 NCI 5R01CA197976-02 The Hippo/YAP Signaling Pathway in Ovarian High Grade Serous Carcinoma WANG, CHENG UNIVERSITY OF NEBRASKA MEDICAL CENTER NE $53,746
Ovarian Cancer 2017 NIGMS 5R35GM118026-02 Mechanisms of Genome Integrity GREENE, ERIC COLUMBIA UNIVERSITY HEALTH SCIENCES NY $537,987
Ovarian Cancer 2017 NCI 5R01CA175480-05 Tumor-targeted Polymersomes to image and Treat Ovarian Cancer CHENG, ZHILIANG UNIVERSITY OF PENNSYLVANIA PA $327,536
Ovarian Cancer 2017 NCI 5R01CA132755-10 Molecular Mechanisms of BRCA1-Dependent DNA Damage Response and Tumorogenesis YU, XIAOCHUN BECKMAN RESEARCH INSTITUTE/CITY OF HOPE CA $382,500
Ovarian Cancer 2017 NIGMS 5R35GM118175-02 Homologous recombination mechanisms in mammalian cells JASIN, MARIA SLOAN-KETTERING INST CAN RESEARCH NY $531,434
Ovarian Cancer 2017 NCI 5U01CA200462-02 MD Anderson Cancer Center EDRN- CVC for Early Detection of Ovarian Cancer BAST, ROBERT UNIVERSITY OF TX MD ANDERSON CAN CTR TX $889,216
Ovarian Cancer 2017 NCI 5U01CA152637-07 Breast, Colorectal, and Ovary Cancer Clinical Validation Center LI, CHRISTOPHER FRED HUTCHINSON CANCER RESEARCH CENTER WA $972,870
Ovarian Cancer 2017 NCI 1U01CA214114-01 Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit PAULOVICH, AMANDA FRED HUTCHINSON CANCER RESEARCH CENTER WA $1,507,572
Ovarian Cancer 2017 NCI 5F32CA196008-03 Elucidation of the impact of commonly co-altered genes on chemosensitivity using a novel model of high-grade serous ovarian cancer CHEN, HSING-YU HARVARD MEDICAL SCHOOL MA $17,460
Ovarian Cancer 2017 OD 1S10OD023508-01 Pre-Clinical 7T MRI for Oklahoma TOWNER, RHEAL OKLAHOMA MEDICAL RESEARCH FOUNDATION OK $600,000
Ovarian Cancer 2017 OD 1S10OD021669-01A1 Purchase of a PerkinElmer IVIS SpectrumCT Imaging System LIEBERMAN, PAUL WISTAR INSTITUTE PA $579,346
Ovarian Cancer 2017 OD 1S10OD023658-01 Purchase of a Seahorse Bioscience XF Analyzer MURPHY, MAUREEN WISTAR INSTITUTE PA $188,255
Ovarian Cancer 2017 NCI 5R01CA172272-05 The BARD1 tumor suppressor and breast cancer BAER, RICHARD COLUMBIA UNIVERSITY HEALTH SCIENCES NY $332,000
Ovarian Cancer 2017 NCI 5R01CA195670-03 The Tumor Suppressor Role of SMARCA4 in SCCOHT WEISSMAN, BERNARD UNIV OF NORTH CAROLINA CHAPEL HILL NC $718,667
Ovarian Cancer 2017 NCI 5K07CA201013-02 Health Services Career Development: Improving Medical Decisions in Ovarian Cancer MEYER, LARISSA UNIVERSITY OF TX MD ANDERSON CAN CTR TX $170,506
Ovarian Cancer 2017 NCI 5R01CA176166-04 Identifying Biomarkers of Cisplatin Resistance Mechanisms in Ovarian Cancer CANTOR, SHARON UNIV OF MASSACHUSETTS MED SCH WORCESTER MA $347,563
Ovarian Cancer 2017 NCI 1R01CA200507-01A1 Optimizing Delivery of Oncolytic Measles Virus Strains with Cell Carriers GALANIS, EVANTHIA MAYO CLINIC ROCHESTER MN $509,698
Ovarian Cancer 2017 NCI 5R01CA177909-05 Platelets promote growth of ovarian cancer AFSHAR-KHARGHAN, VAHID UNIVERSITY OF TX MD ANDERSON CAN CTR TX $332,000
Ovarian Cancer 2017 NCI 2P30CA006973-54 8090 Breast and Ovarian Cancer Program - 08 STEARNS, VERED JOHNS HOPKINS UNIVERSITY MD $36,867
Ovarian Cancer 2017 NIGMS 1SC2GM122686-01 Targeted Promoter Demethylation in Ovarian Cancer Cells SUNG, CHANG TEXAS A&M UNIVERSITY-KINGSVILLE TX $137,999
Ovarian Cancer 2017 NCI 5R01CA193965-02 Redefining Normal: personalized CA125 cutpoints for ovarian cancer screening TERRY, KATHRYN BRIGHAM AND WOMEN'S HOSPITAL MA $394,683
Ovarian Cancer 2017 NCI 5R01CA155025-07 The role of a BRCA1 associated complex in DNA damage response and tumor suppression WANG, BIN UNIVERSITY OF TX MD ANDERSON CAN CTR TX $380,000
Ovarian Cancer 2017 NCI 5K12CA090628-17 Paul Calabresi Program in Clinical/Translational Research at Mayo Clinic JATOI, AMINAH MAYO CLINIC ROCHESTER MN $810,000
Ovarian Cancer 2017 NCI 5R01CA178687-06 Effects of Common Polymorphisms in Immune Sensors in Tumor Immunosurveillance CONEJO-GARCIA, JOSE H. LEE MOFFITT CANCER CTR & RES INST FL $356,900
Ovarian Cancer 2017 NCI 5R01CA193136-03 MDSCs in Ovarian Cancer ZOU, WEIPING UNIVERSITY OF MICHIGAN MI $498,257
Ovarian Cancer 2017 NCI 5R01CA166907-05 Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity RAMKUMAR, VICKRAM SOUTHERN ILLINOIS UNIVERSITY SCH OF MED IL $301,907
Ovarian Cancer 2017 NICHD 5R01HD083930-02 Cryopreservation and Transplantation of Ovarian Cortical Tissue for Fertility Preservation ZELINSKI, MARY OREGON HEALTH & SCIENCE UNIVERSITY OR $627,191
Ovarian Cancer 2017 NCI 1R01CA214545-01 Targeting Kinesin Family Member 15 for the Treatment of Cancer GODWIN, ANDREW UNIVERSITY OF KANSAS MEDICAL CENTER KS $641,589
Ovarian Cancer 2017 NCI 1R01CA215587-01 Multi-Modal Imaging of Psychostimulant Effects on Executive Function Post-RRSO EPPERSON, C. NEILL UNIVERSITY OF PENNSYLVANIA PA $548,965
Ovarian Cancer 2017 NCI 1R01CA214567-01 Isozyme-selective ALDH Inhibitors for Sensitizing Ovarian Cancer Stem-like Cells to Chemotherapy LARSEN, SCOTT UNIVERSITY OF MICHIGAN MI $636,181
Ovarian Cancer 2017 NCI 1R01CA215483-01 Experimental Therapeutics by targeting Spleen Tyrosine Kinase SHIH, IE-MING JOHNS HOPKINS UNIVERSITY MD $374,208
Ovarian Cancer 2017 NCI 5R01CA176078-04 Dissecting the role of STAT3 and targeting ovarian cancer KARUPPAIYAH, SELVENDIRAN OHIO STATE UNIVERSITY OH $320,524
Ovarian Cancer 2017 NCI 5R01CA188571-03 DYRK1A signaling in control of cell growth, proliferation and DNA damage repair LITOVCHICK, LARISA VIRGINIA COMMONWEALTH UNIVERSITY VA $341,494
Ovarian Cancer 2017 NCI 5R21CA202745-02 Dim light at night alters pancreatic cell signaling and predisposes to pancreatic adenocarcinoma NELSON, RANDY OHIO STATE UNIVERSITY OH $167,475
Ovarian Cancer 2017 NCI 5R01CA199004-03 Targeting the vascularity for delivery of inhibitors of metastasis in ovarian cancer MOR, GIL YALE UNIVERSITY CT $511,177
Ovarian Cancer 2017 NCI 5R01CA188900-03 Novel immunological biomarkers ovarian cancer prognosis SEGAL, BRAHM ROSWELL PARK CANCER INSTITUTE CORP NY $646,389
Ovarian Cancer 2017 NCI 5U01CA116167-10 BRCA1 and BRCA2 missense mutations and breast cancer risk COUCH, FERGUS MAYO CLINIC ROCHESTER MN $527,128
Ovarian Cancer 2017 NCI 5R01CA157664-08 Initiation and Evolution of the Ovarian Cancer Microenvironment CONEJO-GARCIA, JOSE H. LEE MOFFITT CANCER CTR & RES INST FL $372,820
Ovarian Cancer 2017 NCI 5R01CA204019-02 Multiplexed analysis of exosomes in cancer nano therapy WEISSLEDER, RALPH MASSACHUSETTS GENERAL HOSPITAL MA $389,111
Ovarian Cancer 2017 NCI 1R21CA210210-01A1 Targeting Cyclin E in Ovarian Cancer with Histone Deacetylase Inhibitors KHABELE, DINEO UNIVERSITY OF KANSAS MEDICAL CENTER KS $182,020
Ovarian Cancer 2017 NCI 1R01CA209818-01A1 Tumor-targeted nanoparticle-based delivery system for imaging and treatment of cancer MINKO, TAMARA RUTGERS, THE STATE UNIV OF N.J. NJ $470,010
Ovarian Cancer 2017 NIBIB 1R21EB024101-01 Microfluidic Integrative Circulating miRNA Profiling for Cancer Diagnosis ZENG, YONG UNIVERSITY OF KANSAS LAWRENCE KS $230,605
Ovarian Cancer 2017 NCI 5R01CA131582-08 Identification of Ovarian Cancer Plasma Biomarkers SPEICHER, DAVID WISTAR INSTITUTE PA $452,569
Ovarian Cancer 2017 NCI 5R00CA184043-05 Targeting Ovarian Cancer via Cooperative Oncogene Interactions HARGREAVES, DIANA SALK INSTITUTE FOR BIOLOGICAL STUDIES CA $249,000
Ovarian Cancer 2017 NCI 5R01CA184717-04 The Regulation of Cisplatin resistance in ovarian cancer ZHU, WENGE GEORGE WASHINGTON UNIVERSITY DC $328,888
Ovarian Cancer 2017 NCI 5R01CA188251-04 Molecular Insights into the Fanconi Anemia Tumor Suppressor Signaling Pathway FEI, PEIWEN UNIVERSITY OF HAWAII AT MANOA HI $319,550
Ovarian Cancer 2017 NCI 5R01CA207034-02 Mechanism of evasion by ovarian cancers from anti-VEGF therapy NAORA, HONAMI UNIVERSITY OF TX MD ANDERSON CAN CTR TX $366,000
Ovarian Cancer 2017 NCI 5K22CA193860-02 PCOS, Type II diabetes and ovarian cancer risk HARRIS, HOLLY FRED HUTCHINSON CANCER RESEARCH CENTER WA $184,615
Ovarian Cancer 2017 NCI 5R01CA197359-03 Stem Cell/Nanoparticle Constructs for Targeted Ovarian Cancer Therapy BERLIN, JACOB BECKMAN RESEARCH INSTITUTE/CITY OF HOPE CA $388,875
Ovarian Cancer 2017 NCI 1R01CA207260-01A1 Exploring factors related to racial disparities in ovarian cancer incidence and survival: the OCWAA consortium SCHILDKRAUT, JOELLEN UNIVERSITY OF VIRGINIA VA $700,701
Ovarian Cancer 2017 NCI 1R01CA215797-01 Obesity Increases Breast Cancer Penetrance in BRCA Mutation Carriers: A Role for Local and Systemic Factors DANNENBERG, ANDREW WEILL MEDICAL COLL OF CORNELL UNIV NY $515,275
Ovarian Cancer 2017 NCI 5R01CA193578-03 Tunable Microchip Sorting of BRCA1 Nuclear Assemblies KELLY, DEBORAH VIRGINIA POLYTECHNIC INST AND ST UNIV VA $358,506
Ovarian Cancer 2017 NCI 5P50CA159981-05 5590 Inhibition of indole-amine 2,3 dioxygenase to Enhance Ovarian Tumor Immunity ODUNSI, KUNLE ROSWELL PARK CANCER INSTITUTE CORP NY $571,869
Ovarian Cancer 2017 NCI 5P50CA159981-05 5591 Rapamycin and IL-21 Conditioned CD8+ T Cells for Adoptive Cellular Therapy of Ov SHRIKANT, PROTUL ROSWELL PARK CANCER INSTITUTE CORP NY $605,749
Ovarian Cancer 2017 NCI 5P50CA159981-05 5593 MHC-Restricted and MHC-Non-Restricted Targeting of Ovarian Cancer by alphaDC1 KALINSKI, PAWEL UNIVERSITY OF PITTSBURGH PA $639,310
Ovarian Cancer 2017 NCI 5P50CA159981-05 5595 Administrative Core ODUNSI, KUNLE ROSWELL PARK CANCER INSTITUTE CORP NY $81,606
Ovarian Cancer 2017 NCI 5P50CA159981-05 5596 Biospecimen Core MORRISON, CARL ROSWELL PARK CANCER INSTITUTE CORP NY $81,190
Ovarian Cancer 2017 NCI 5P50CA159981-05 5597 Biostatistics/Medical Informatics HUTSON, ALAN ROSWELL PARK CANCER INSTITUTE CORP NY $66,966
Ovarian Cancer 2017 NCI 5P50CA159981-05 5598 Immune Monitoring Core WALLACE, PAUL ROSWELL PARK CANCER INSTITUTE CORP NY $106,356
Ovarian Cancer 2017 NCI 5P50CA159981-05 5599 Developmental Research Program MOYSICH, KIRSTEN ROSWELL PARK CANCER INSTITUTE CORP NY $76,662
Ovarian Cancer 2017 NCI 5P50CA159981-05 5600 Career Development Program LELE, SHASHIKANT ROSWELL PARK CANCER INSTITUTE CORP NY $70,292
Ovarian Cancer 2017 NHLBI 1R01HL132251-01A1 The Roles and Regulation of BRCA1 in Hematopoiesis ROSS, THEODORA UT SOUTHWESTERN MEDICAL CENTER TX $405,000
Ovarian Cancer 2017 NCI 5R01CA190237-03 Targeting BRCA Deficient Cells for Killing POMERANTZ, RICHARD TEMPLE UNIV OF THE COMMONWEALTH PA $356,850
Ovarian Cancer 2017 NCI 1R01CA216234-01 Role of microbiota in therapy to ovarian cancer RANDALL, TROY UNIVERSITY OF ALABAMA AT BIRMINGHAM AL $426,139
Ovarian Cancer 2017 NCI 1R03CA216127-01 A New Ovarian Cancer Mouse Model Based on Nanoparticle Gene Delivery YANG, YANG YALE UNIVERSITY CT $77,000
Ovarian Cancer 2017 NCI 1R01CA207407-01A1 Generating rapid antitumor immunity with lymphocyte-reprogramming nanocarriers STEPHAN, MATTHIAS FRED HUTCHINSON CANCER RESEARCH CENTER WA $371,925
Ovarian Cancer 2017 NCI 1R03CA208573-01A1 Metformin Supplementation for Ovarian Cancer Prevention: A Prospective Preclinical Study RAMACHANDRAN, RAMESH PENNSYLVANIA STATE UNIVERSITY-UNIV PARK PA $78,600
Ovarian Cancer 2017 NCI 1R03CA208494-01A1 Development of Cell-based Functional Tests for Rare Germline ATM Gene Variants in Hereditary Ovarian Cancer Families TAINSKY, MICHAEL WAYNE STATE UNIVERSITY MI $77,000
Ovarian Cancer 2017 NCI 5F30CA203095-02 Transcriptomic profiling and functional characterization of fusion genes in recurrent ovarian cancer PRIEDIGKEIT, NOLAN UNIVERSITY OF PITTSBURGH AT PITTSBURGH PA $49,044
Ovarian Cancer 2017 NCI 5K12CA076930-17 Career Development in Pediatric and Medical Oncology BERNSTEIN, IRWIN FRED HUTCHINSON CANCER RESEARCH CENTER WA $701,719
Ovarian Cancer 2017 NCI 1R01CA208244-01A1 Investigating 53BP1 'dephosphorylation' as a critical determinant of PARP CHOWDHURY, DIPANJAN DANA-FARBER CANCER INST MA $385,557
Ovarian Cancer 2017 NCI 1R21CA204036-01A1 In vivo anti-PD1 gene therapy LIEBER, ANDRE UNIVERSITY OF WASHINGTON WA $202,112
Ovarian Cancer 2017 NCI 5R35CA197458-03 GENOMIC ANALYSIS OF INHERITED BREAST AND OVARIAN CANCER KING, MARY-CLAIRE UNIVERSITY OF WASHINGTON WA $927,000
Ovarian Cancer 2017 NCI 1K99CA207729-01A1 Copy Number Alterations in Low Mutation Cancer DELANEY, JOE UNIVERSITY OF CALIFORNIA SAN DIEGO CA $118,896
Ovarian Cancer 2017 NIGMS 2R01GM097272-06A1 Cellular responses to DNA replication stress SMOLKA, MARCUS CORNELL UNIVERSITY NY $332,001
Ovarian Cancer 2017 NCI 5R01CA210370-02 Early detection of ovarian cancer by serum marker and targeted ultrasound imaging BARUA, ANIMESH RUSH UNIVERSITY MEDICAL CENTER IL $356,180
Ovarian Cancer 2017 NCI 5F30CA192648-03 Deciphering Links Between Inflammation and Cancer with IMP-1 Inhibitors MAHAPATRA, LILY UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN IL $49,044
Ovarian Cancer 2017 NCI 5R01CA196200-03 Ovarian Cancer Chemoprevention BENBROOK, DORIS UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR OK $500,225
Ovarian Cancer 2017 NCI 5K07CA166210-05 Chemotherapy Near Death: Modifiable Factors and Outcomes in Ovarian Cancer WRIGHT, ALEXI DANA-FARBER CANCER INST MA $177,120
Ovarian Cancer 2017 NCI 5R01CA135354-07 ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer BAST, ROBERT UNIVERSITY OF TX MD ANDERSON CAN CTR TX $380,000
Ovarian Cancer 2017 NINR 5F31NR015170-03 Hormone Therapy Decision Making in Older Women HUNTER, MARY UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CA $35,495
Ovarian Cancer 2017 NCI 5F32CA200357-02 Role of Follicular Fluid Exosomes on Ovarian/Fallopian Carcinogenesis BRACHOVA, PAVLA UNIVERSITY OF KANSAS MEDICAL CENTER KS $59,166
Ovarian Cancer 2017 NCI 5P30CA036727-31 5725 Molecular and Biochemical Etiology (MBE) BAND, HAMID UNIVERSITY OF NEBRASKA MEDICAL CENTER NE $66,915
Ovarian Cancer 2017 NCI 5R01CA188943-03 Discovery of Novel Rare Variants as Ovarian Cancer Susceptibility Factors HILDEBRANDT, MICHELLE UNIVERSITY OF TX MD ANDERSON CAN CTR TX $1,225,214
Ovarian Cancer 2017 NCI 5R01CA188025-04 Iron addiction and the biology of ovarian cancer TORTI, SUZY UNIVERSITY OF CONNECTICUT SCH OF MED/DNT CT $334,085
Ovarian Cancer 2017 NCI 5R21CA209848-02 Algorithms for Literature-Guided Multi-Platform Identification of Cancer Subtypes CHUNG, DONGJUN MEDICAL UNIVERSITY OF SOUTH CAROLINA SC $162,581
Ovarian Cancer 2017 NCI 5R01CA181663-02 Mechanisms of radioresistance and strategies for radiosensitization in OCCC PENG, GUANG UNIVERSITY OF TX MD ANDERSON CAN CTR TX $1
Ovarian Cancer 2017 NCI 5R01CA131407-10 Re-activating Memory T Cells in the Microenvironment of Human Tumors BANKERT, RICHARD STATE UNIVERSITY OF NEW YORK AT BUFFALO NY $326,466
Ovarian Cancer 2017 NCI 5K22CA181611-03 Online monitoring and image-guided treatment of chemoresistant micrometastases SPRING, BRYAN NORTHEASTERN UNIVERSITY MA $186,251
Ovarian Cancer 2017 RMAP 5R21CA207816-02 Integrated Digital Microfluidic Platforms for Next-Generation Glycomics ZENG, YONG UNIVERSITY OF KANSAS LAWRENCE KS $292,724
Ovarian Cancer 2017 NCI 5R01CA187209-04 Functional analysis of BRCA1 in DNA damage response and tumor suppression YU, XIAOCHUN BECKMAN RESEARCH INSTITUTE/CITY OF HOPE CA $352,750
Ovarian Cancer 2017 NCI 5R01CA207497-02 Provectors for treatment of ovarian cancer SUH, JUNGHAE RICE UNIVERSITY TX $352,623
Ovarian Cancer 2017 NCI 5P30CA047904-29 6390 Breast and Ovarian Cancer Program (Project-007) LEE, ADRIAN UNIVERSITY OF PITTSBURGH AT PITTSBURGH PA $34,500
Ovarian Cancer 2017 RMAP 5UH3TR000943-05 Novel extra cellular RNA-based combinatorial RNA inhibition therapy SOOD, ANIL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $1,000,000
Ovarian Cancer 2017 NCI 5SC2CA206194-03 Theranostic nanoparticles for dual modality cancer therapy CZAJKOWSKA, ANETA BROOKLYN COLLEGE NY $157,000
Ovarian Cancer 2017 NCI 5R01CA142746-08 Enzyme-instructed self-assembly for molecular anticancer nanomedicines XU, BING BRANDEIS UNIVERSITY MA $368,145
Ovarian Cancer 2017 NCI 5R21CA209281-02 Development of DNA Polymerase θ Inhibitors for Precision Medicine in BRCA Deficient Cancers POMERANTZ, RICHARD TEMPLE UNIV OF THE COMMONWEALTH PA $169,650
Ovarian Cancer 2017 NCI 5R01CA102310-14 Role of FAK in Tumorigenesis SCHLAEPFER, DAVID UNIVERSITY OF CALIFORNIA SAN DIEGO CA $331,313
Ovarian Cancer 2017 NCI 5R00CA184415-04 Functional Analysis of LncRNAs in Epithelial Ovarian Cancer LAWRENSON, KATE CEDARS-SINAI MEDICAL CENTER CA $227,414
Ovarian Cancer 2017 NCI 5P01CA087969-18 8092 Core A: Biospecimen and High-Dimensional Data Management Core TWOROGER, SHELLEY BRIGHAM AND WOMEN'S HOSPITAL MA $629,241
Ovarian Cancer 2017 NCI 5P01CA087969-18 8096 Project 3: Ovarian Cancer TWOROGER, SHELLEY BRIGHAM AND WOMEN'S HOSPITAL MA $326,903
Ovarian Cancer 2017 NCI 5P01CA087969-18 8097 Project 4: Statistical Innovations ROSNER, BERNARD BRIGHAM AND WOMEN'S HOSPITAL MA $167,985
Ovarian Cancer 2017 NCI 1F30CA217079-01 FemKube, the human female reproductive tract-on-a-chip, as a platform for studying high grade serous ovarian cancer and developing novel cancer chemotherapeutics YOUNG, ALEXANDRIA UNIVERSITY OF ILLINOIS AT CHICAGO IL $44,044
Ovarian Cancer 2017 NCI 5R01CA180710-05 Targeting nucleotide excision repair in combination cancer therapy TURCHI, JOHN INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS IN $323,700
Ovarian Cancer 2017 NICHD 5R01HD073499-05 Genetic regulation of ovariole development in Drosophila EXTAVOUR, CASSANDRA HARVARD UNIVERSITY MA $317,348
Ovarian Cancer 2017 NCI 5R01CA181808-04 Steroid Hormones Regulate Ovarian Cancer Progression and Metastasis RICHARDS, JOANNE BAYLOR COLLEGE OF MEDICINE TX $336,565
Ovarian Cancer 2017 NCI 1R01CA211648-01A1 Identifying the Drivers and Targeting Chemo Resistance in Ovarian Cancer ADLI, MAZHAR UNIVERSITY OF VIRGINIA VA $429,211
Ovarian Cancer 2017 NIGMS 5R35GM119512-02 Connecting BRCA1 functions with DNA crosslink sensitivity LONG, DAVID MEDICAL UNIVERSITY OF SOUTH CAROLINA SC $373,750
Ovarian Cancer 2017 NCI 1R43CA213538-01A1 Improving delivery of paclitaxel to ovarian cancer via expansile nanoparticles COLBY, AARON IONIC PHARMACEUTICALS MA $283,122
Ovarian Cancer 2017 NCI 5K22CA181550-03 Targeting defective DNA repair for the prevention of BRCA1-associated cancers ALLI, ELIZABETH WAKE FOREST UNIVERSITY HEALTH SCIENCES NC $162,000
Ovarian Cancer 2017 NCI 5R00CA166228-05 A Pathway-based approach to investigate oncogenic mechanisms in ovarian cancer GATZA, MICHAEL RBHS -CANCER INSTITUTE OF NEW JERSEY NJ $249,000
Ovarian Cancer 2017 NCI 5P01CA190174-03 7470 Adminstrative Core SPRIGGS, DAVID SLOAN-KETTERING INST CAN RESEARCH NY $104,237
Ovarian Cancer 2017 NCI 5P01CA190174-03 7471 Biostatistics Core IASONOS, ALEXIA SLOAN-KETTERING INST CAN RESEARCH NY $81,105
Ovarian Cancer 2017 NCI 5P01CA190174-03 7472 Pathology Core DELAIR, DEBORAH SLOAN-KETTERING INST CAN RESEARCH NY $104,236
Ovarian Cancer 2017 NCI 5P01CA190174-03 7473 MUC16 Antibody Based Strategies for Imaging and Therapy SPRIGGS, DAVID SLOAN-KETTERING INST CAN RESEARCH NY $729,636
Ovarian Cancer 2017 NCI 5P01CA190174-03 7474 Personalized Immunotherapy of Patients with Ovarian Cancer SABBATINI, PAUL SLOAN-KETTERING INST CAN RESEARCH NY $625,397
Ovarian Cancer 2017 NCI 5P01CA190174-03 7476 Enhanced Efficacy of MUC16 directed antibodies through modification of the Fc domain RAVETCH, JEFFREY SLOAN-KETTERING INST CAN RESEARCH NY $389,221
Ovarian Cancer 2017 NCI 5P50CA136393-08 7019 Biospecimens and Patient Registry KEENEY, GARY MAYO CLINIC ROCHESTER MN $134,451
Ovarian Cancer 2017 NCI 5P50CA136393-08 7020 Core C - Biostatistics Core OBERG, ANN MAYO CLINIC ROCHESTER MN $156,342
Ovarian Cancer 2017 NCI 5P50CA136393-08 7021 Core D - Animal Models Core HALUSKA, PAUL MAYO CLINIC ROCHESTER MN $149,342
Ovarian Cancer 2017 NCI 5P50CA136393-08 7022 Administrative Core KAUFMANN, SCOTT MAYO CLINIC ROCHESTER MN $575,779
Ovarian Cancer 2017 NCI 5P50CA136393-08 7023 Project 1 - PARP Project KAUFMANN, SCOTT MAYO CLINIC ROCHESTER MN $188,670
Ovarian Cancer 2017 NCI 5P50CA136393-08 7024 Project 6 - PKC Iota FIELDS, ALAN MAYO CLINIC ROCHESTER MN $285,273
Ovarian Cancer 2017 NCI 5P50CA136393-08 7025 Project 7 - Metformin LENGYEL, ERNST MAYO CLINIC ROCHESTER MN $354,105
Ovarian Cancer 2017 NCI 5P50CA136393-08 7026 Project 8 - TH17 Dendritic Cell Vaccine KNUTSON, KEITH MAYO CLINIC ROCHESTER MN $306,631
Ovarian Cancer 2017 NCI 5P50CA136393-08 7027 Developmental Reserach Pilot Projects CLIBY, WILLIAM MAYO CLINIC ROCHESTER MN $99,606
Ovarian Cancer 2017 NCI 5P50CA136393-08 7028 Career Development GOODE, ELLEN MAYO CLINIC ROCHESTER MN $49,801
Ovarian Cancer 2017 NCI 5R21CA208610-02 Pax2 loss in fallopian tube lesions and strategies for restoration in serous cancer BURDETTE, JOANNA UNIVERSITY OF ILLINOIS AT CHICAGO IL $163,017
Ovarian Cancer 2017 NCI 1R01CA214043-01A1 Macrophage-based ovarian cancer immunotherapy YULL, FIONA VANDERBILT UNIVERSITY TN $371,717
Ovarian Cancer 2017 NCI 5F31CA192891-04 Evaluating Notch Signaling as a Therapeutic Target in Ovarian Cancer PRICE, JESSICA COLUMBIA UNIVERSITY HEALTH SCIENCES NY $49,044
Ovarian Cancer 2017 NCI 5U01CA202144-03 Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics ALTER, ORLY UNIVERSITY OF UTAH UT $704,509
Ovarian Cancer 2017 NCATS 5R21TR001731-02 Ketorolac and Related NSAIDs for Targeting Rho-family GTPases in Ovarian Cancer WANDINGER-NESS, ANGELA UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR NM $303,000
Ovarian Cancer 2017 NCI 5R01CA207456-02 Epidemiology and biology of lncRNAs in ovarian cancer SELLERS, THOMAS H. LEE MOFFITT CANCER CTR & RES INST FL $951,947
Ovarian Cancer 2017 NCI 5U24CA209999-02 Monitoring tumor subclonal heterogeneity over time and space MARTH, GABOR UNIVERSITY OF UTAH UT $751,812
Ovarian Cancer 2017 NCI 5P50CA116201-12 8257 01 Project 1: Cancer risks for mutations in breast cancer predisposition genes COUCH, FERGUS MAYO CLINIC ROCHESTER MN $494,441
Ovarian Cancer 2017 NCI 5R44CA203350-03 Genetic Cytology for Ovarian and Endometrial Cancer Screening KINDE, ISAAC PAPGENE, INC. MD $994,554
Ovarian Cancer 2017 NCI 5UM1CA182910-05 Shanghai Womens Health Study ZHENG, WEI VANDERBILT UNIVERSITY MEDICAL CENTER TN $1,321,497
Ovarian Cancer 2017 NCI 5R01CA208753-02 Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid Malignancies ORSULIC, SANDRA CEDARS-SINAI MEDICAL CENTER CA $400,313
Ovarian Cancer 2017 NCI 1R41CA213479-01A1 Investigation of antibody-drug conjugates of a novel target CUI, JIE WNTRIX, INC. TX $225,000
Ovarian Cancer 2017 NCI 5R44CA206606-02 A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy WINRAM, SCOTT CYNVEC, LLC NY $1,004,186
Ovarian Cancer 2017 NCATS 1R43TR002043-01 Reconstituted High Density Lipoprotein Particles as siRNA Carriers CHATTERJEE, DEV FANNIN PARTNERS, LLC TX $324,593
Ovarian Cancer 2017 NCI 1U54CA209978-01A1 8334 Project 1: Dynamic Genomic and Microenvironmental Models of Acquired Chemoresistance BILD, ANDREA UNIVERSITY OF UTAH UT $434,320
Ovarian Cancer 2017 NCI 1U54CA209978-01A1 8335 Project 2: Targeting Cooperative Phenotypes Common in Spatial Heterogeneity CHANG, JEFFREY UNIVERSITY OF UTAH UT $331,274
Ovarian Cancer 2017 NCI 7K08CA211362-02 Defining the formation and function of carcinoma-associated mesenchymal stem cells in the ovarian cancer microenvironment COFFMAN, LAN UNIVERSITY OF PITTSBURGH AT PITTSBURGH PA $166,050
Ovarian Cancer 2017 NIBIB 5R01EB020605-02 Advanced Salpingoscope for Minimally-Invasive Imaging of the Fallopian Tubes BARTON, JENNIFER UNIVERSITY OF ARIZONA AZ $334,425
Ovarian Cancer 2017 NCI 5R01CA172404-05 Identifying Prognostic Markers and Therapeutic Targets for Serous Ovarian Cancer RAMUS, SUSAN UNIVERSITY OF NEW SOUTH WALES AUSTRA $483,257
Ovarian Cancer 2017 NIGMS 5R01GM059078-18 Molecular Probes for Biomembrane Recognition SMITH, BRADLEY UNIVERSITY OF NOTRE DAME IN $376,671
Ovarian Cancer 2017 NCI 5U24CA210954-02 iPGDAC, An Integrative Proteogenomic Data Analysis Center for CPTAC ZHANG, BING BAYLOR COLLEGE OF MEDICINE TX $973,045
Ovarian Cancer 2017 NCI 5R50CA211280-02 Discovery and Characterization of Mutations in Breast and Ovarian Cancers ADAMSON, AARON BECKMAN RESEARCH INSTITUTE/CITY OF HOPE CA $215,047
Ovarian Cancer 2017 NCI 5F99CA212222-02 Inflammation and gynecologic cancer: the role of prostaglandins in ovarian cancer BARNARD, MOLLIE HARVARD SCHOOL OF PUBLIC HEALTH MA $31,260
Ovarian Cancer 2017 NCI 5F99CA212470-02 FOXM1-RHNO1 Oncogenic Axis in Ovarian Cancer BARGER, CARTER UNIVERSITY OF NEBRASKA MEDICAL CENTER NE $31,739
Ovarian Cancer 2017 NCI 5F99CA212460-02 Identifying epigenetic drivers and their targets in aggressive breast and ovarian cancers SAHNI (BRANCATO), JENNIFER CASE WESTERN RESERVE UNIVERSITY OH $33,366
Ovarian Cancer 2017 NCI 5U54CA163069-07 6965 Roles of proinflammatory chemokines linking obesity and ovarian cancer SON, DEOK-SOO MEHARRY MEDICAL COLLEGE TN $80,108
Ovarian Cancer 2017 NCI 5U54CA163072-08 6543 Roles of proinflammatory chemokines linking obesity and ovarian cancer BEEGHLY-FADIEL, ALICIA VANDERBILT UNIVERSITY MEDICAL CENTER TN $18,696
Ovarian Cancer 2017 NCI 5U24CA210955-02 PNNL Proteome Characterization Center LIU, TAO BATTELLE PACIFIC NORTHWEST LABORATORIES WA $1,091,415
Ovarian Cancer 2017 NCI 1P50CA217685-01 5104 Administrative Core BAST, ROBERT UNIVERSITY OF TX MD ANDERSON CAN CTR TX $157,400
Ovarian Cancer 2017 NCI 1P50CA217685-01 5105 Core 1: Pathology Core BROADDUS, RUSSELL UNIVERSITY OF TX MD ANDERSON CAN CTR TX $216,576
Ovarian Cancer 2017 NCI 1P50CA217685-01 5106 Core 2: Bioinformatics and Biostatistics Core BAGGERLY, KEITH UNIVERSITY OF TX MD ANDERSON CAN CTR TX $165,080
Ovarian Cancer 2017 NCI 1P50CA217685-01 5107 Project 1: High Grade Cancers: Capitalizing on PARPness in Ovarian Carcinoma MILLS, GORDON UNIVERSITY OF TX MD ANDERSON CAN CTR TX $351,522
Ovarian Cancer 2017 NCI 1P50CA217685-01 5109 Project 3: The Role of Macrophages in Resistance to Anti-VEGF Drugs in Ovarian Cancer COLEMAN, ROBERT UNIVERSITY OF TX MD ANDERSON CAN CTR TX $351,941
Ovarian Cancer 2017 NCI 1P50CA217685-01 5110 Project 4: SIK2 PROVIDES A NOVEL TARGET FOR OVARIAN CANCER THERAPY IN COMBINATION WITH PACLITAXEL AND INHIBITORS OF PARP BAST, ROBERT UNIVERSITY OF TX MD ANDERSON CAN CTR TX $338,337
12


  • Download Readers:
  • Download Adobe PDF Reader
  • Download Microsoft PowerPoint Viewer
  • Download Microsoft Word Viewer
  • Download Microsoft Excel Viewer